title: Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML.
abstract: The monitoring of the minimal residual disease by Wilms' tumor 1 expression (MRDWT1) is a standardized test, which can be used in over 80% of patients with AML. To investigate the prognostic value of MRDWT1in patients undergoing allogeneic stem cell transplantation (allo-SCT) for AML, MRDWT1was monitored 3 months after transplantation in 139 patients. MRDWT1positivity did not lead to any therapeutic intervention. Median follow-up was 39.3 (6.4-99.8) months. Patients with positive MRDWT1at 3 months experienced more often post-transplant relapse (27/30, 90%) than those with negative MRDWT1(16/109, 14.7%) (P<0.0001). Similarly, a shorter 3-year event-free survival (EFS) was observed in MRDWT1-positive patients (10% vs 72.3% in MRDWT1-negative patients, P<0.0001). The correlation between relapse and MRDWT1was stronger in blood than in bone marrow samples. Multivariate analysis confirmed the detrimental role of 3-month positive MRDWT1for relapse (hazard ratio (HR): 15.42; 95% confidence interval (CI): 7.53-31.59; P<0.0001) and EFS (HR: 10.71; 95% CI: 5.41-21.21; P<0.0001). Interestingly, 3-month chimerism was less predictive of relapse than positive MRDWT1. In conclusion, our results demonstrate the usefulness of peripheral blood MRDWT1monitoring in identifying very high-risk patients, who could benefit from an early preemptive treatment, and those who do not need such an intervention.
authors.affiliation: Department of Hematology and Bone Marrow Transplantation, CHRU de Lille, Lille, France.|University of Lille Nord de France, Lille, France.|Inserm, UMRs 837, Team 3, Cancer Research Institute of Lille, Lille, France.
authors.forename: R
authors.initials: R
authors.lastname: Duléry
authors.affiliation: University of Lille Nord de France, Lille, France.|Inserm, UMRs 837, Team 3, Cancer Research Institute of Lille, Lille, France.|Laboratory of Hematology, Biology and Pathology Center, CHRU of Lille, Lille, France.
authors.forename: O
authors.initials: O
authors.lastname: Nibourel
authors.affiliation: Department of Hematology and Bone Marrow Transplantation, CHRU de Lille, Lille, France.|University of Lille Nord de France, Lille, France.
authors.forename: J
authors.initials: J
authors.lastname: Gauthier
authors.affiliation: University of Lille Nord de France, Lille, France.|Laboratory of Immunology, Biology and Pathology Center, CHRU of Lille, Lille, France.
authors.forename: V
authors.initials: V
authors.lastname: Elsermans
authors.affiliation: University of Lille Nord de France, Lille, France.|Department of Biostatistics, CHRU Lille, Lille, France.
authors.forename: H
authors.initials: H
authors.lastname: Behal
authors.affiliation: Department of Hematology and Bone Marrow Transplantation, CHRU de Lille, Lille, France.|University of Lille Nord de France, Lille, France.
authors.forename: V
authors.initials: V
authors.lastname: Coiteux
authors.affiliation: Department of Hematology and Bone Marrow Transplantation, CHRU de Lille, Lille, France.|University of Lille Nord de France, Lille, France.
authors.forename: L
authors.initials: L
authors.lastname: Magro
authors.affiliation: University of Lille Nord de France, Lille, France.|Inserm, UMRs 837, Team 3, Cancer Research Institute of Lille, Lille, France.|Laboratory of Hematology, Biology and Pathology Center, CHRU of Lille, Lille, France.
authors.forename: A
authors.initials: A
authors.lastname: Renneville
authors.affiliation: University of Lille Nord de France, Lille, France.|Inserm, UMRs 837, Team 3, Cancer Research Institute of Lille, Lille, France.|Laboratory of Hematology, Biology and Pathology Center, CHRU of Lille, Lille, France.
authors.forename: A
authors.initials: A
authors.lastname: Marceau
authors.affiliation: University of Lille Nord de France, Lille, France.|Inserm, UMRs 837, Team 3, Cancer Research Institute of Lille, Lille, France.|Laboratory of Hematology, Biology and Pathology Center, CHRU of Lille, Lille, France.
authors.forename: T
authors.initials: T
authors.lastname: Boyer
authors.affiliation: Department of Hematology and Bone Marrow Transplantation, CHRU de Lille, Lille, France.|University of Lille Nord de France, Lille, France.|Inserm, UMRs 837, Team 3, Cancer Research Institute of Lille, Lille, France.
authors.forename: B
authors.initials: B
authors.lastname: Quesnel
authors.affiliation: University of Lille Nord de France, Lille, France.|Inserm, UMRs 837, Team 3, Cancer Research Institute of Lille, Lille, France.|Laboratory of Hematology, Biology and Pathology Center, CHRU of Lille, Lille, France.
authors.forename: C
authors.initials: C
authors.lastname: Preudhomme
authors.affiliation: University of Lille Nord de France, Lille, France.|Laboratory of Immunology, Biology and Pathology Center, CHRU of Lille, Lille, France.
authors.forename: A
authors.initials: A
authors.lastname: Duhamel
authors.affiliation: Department of Hematology and Bone Marrow Transplantation, CHRU de Lille, Lille, France.|University of Lille Nord de France, Lille, France.|LIRC U995, Lille, France.
authors.forename: I
authors.initials: I
authors.lastname: Yakoub-Agha
mesh_terms: D001853:Bone Marrow / Q000737:chemistry; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods / Q000401:mortality*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D018365:Neoplasm, Residual / Q000175:diagnosis*; D011379:Prognosis; D012008:Recurrence; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D025721:WT1 Proteins / Q000032:analysis* / Q000097:blood; D009396:Wilms Tumor / Q000737:chemistry
chemical_list: D025721:WT1 Proteins